11 orbital embryonic rhabdomyosarcomas were studied immunohistochemically from patients under 4 years of age. One out of these cases, undifferentiated, showed to be myoglobin negative, and desmin positive. We point out the importance of this fact in immunohistochemical determination of the specificity of this entity.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000309706DOI Listing

Publication Analysis

Top Keywords

embryonic rhabdomyosarcomas
8
immunohistochemical study
4
study embryonic
4
rhabdomyosarcomas orbital
4
orbital embryonic
4
rhabdomyosarcomas studied
4
studied immunohistochemically
4
immunohistochemically patients
4
patients years
4
years age
4

Similar Publications

Adult Embryonal Rhabdomyosarcoma of the Prostate Presented on 18F-FDG and Al18F-FAPI-74 PET/CT.

Clin Nucl Med

December 2024

From the Department of Nuclear Medicine (PET-CT Center), National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

A 21-year-old man with a 2-week history of abdominal pain and urinary hesitancy was admitted to our hospital. Sarcoma was suspected based on his PSA level, age, and MRI findings. He underwent 18F-FDG and Al18F-FAPI-74 PET/CT scans.

View Article and Find Full Text PDF

Background: The histologic classification of rhabdomyosarcoma (RMS) as alveolar (aRMS) or embryonal (eRMS) is of prognostic importance, with the aRMS being associated with a worse outcome. Specific gene fusions (PAX3/7::FOXO1) found in the majority of aRMS have been recognized as markers associated with poor prognosis and are included in current risk stratification instead of histologic subtypes in localized disease. In metastatic disease, the independent prognostic significance of fusion status has not been definitively established.

View Article and Find Full Text PDF

Background: Rhabdomyosarcoma (RMS) is a highly malignant soft tissue tumor derived from primitive embryonal mesenchymal tissue that differentiates into striated skeletal muscle. Despite the improved outcome based on the EFS and OS using the three different treatment modalities-chemotherapy, radiotherapy and surgical treatment, the survival of patients depends on their IRS groups-pathological and surgical. On the other hand in the last thirty years a great improvement of the five-year overall survival (OS) of children with RMS have been observed based on the results of large multinational collaborative trials and successive studies dedicated to children, though prognosis is variable and dependent on several factors including histologic variant, primary sites of the tumor, extent of disease (disease resectability), and molecular-level characteristics.

View Article and Find Full Text PDF

Head and Neck Rhabdomyosarcoma in Pediatric Patients: An International Collaborative Study.

J Oral Pathol Med

January 2025

Departamento de Diagnóstico Oral, Área de Semiologia e Patologia Oral, Faculdade de Odontologia de Piracicaba, Universidade Estadual de Campinas (FOP-UNICAMP), Piracicaba, Brazil.

Background: Rhabdomyosarcoma (RMS), a rare malignant tumor, frequently affects pediatric patients, with 35%-40% occurring in the head and neck. This study analyzes the clinicopathologic profile of pediatric head and neck rhabdomyosarcomas from Brazil, Guatemala, Mexico, and South Africa.

Methods: We reviewed 44 cases from 10 Oral and Maxillofacial Pathology services, conducting immunohistochemical analyses of desmin, myogenin, Myo-D1, and Ki67, with quantification via QuPath software.

View Article and Find Full Text PDF

Esophageal embryonal rhabdomyosarcoma (ERMS), a rare pediatric cancer, mimicked achalasia in a case involving dysphagia and vomiting. Diagnosis and chemotherapy necessitate careful monitoring due to potential complications. A 12-year-old girl with no prior medical history presented with progressive dysphagia and vomiting.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!